Gilde Healthcare Services invests in nursing homes - Gilde Healthcare

Gilde Healthcare Services invests in nursing homes

October 25, 2010

Utrecht, The Netherlands – Gilde Healthcare Services (Gilde), a growth capital fund specialised in Healthcare Services, has acquired a significant minority stake in elderly care provider Stepping Stones Home & Care (Stepping Stones) of the Netherlands to fund further growth of the company.

Stepping Stones operates a chain of nursing homes providing care for elderly with Alzheimer’s disease and related conditions that need continuous support. The nursing homes offer a safe, protected and continuous care environment with affordable services tailored to the needs of residents (www.steppingstonesbv.nl).

Stepping Stones founding managers Arthur Scherpenzeel and Christiaan Sap commented:

“We are thrilled with the investment from Gilde. This investment not only enables us to expand the number of locations but we will also benefit from Gilde’s hands-on approach and healthcare expertise.

Jasper van Gorp, Partner of the Gilde Healthcare Services fund said:

“We were impressed by Stepping Stones’ ability to provide a very high quality yet affordable care home service. We believe that there is a considerable need for this type of service which can co-exist alongside care provided by the public sector in the Netherlands. This investment is aligned perfectly with our investment focus on high growth healthcare services companies.

Gilde Healthcare company Big Health builds out its Leadership Team with the appointment of five key Executives

Big Health, creators of the leading digital treatments for mental health, has appointed five executives to its senior leadership team as the company enters the next phase in the growth of its business. This follows...
January 12, 2023

Gilde Healthcare company Volta medical secures €36M in Series B funding

Volta Medical, a pioneering health technology company developing artificial intelligence (AI) solutions to assist electrophysiologist physicians in treating complex cardiac arrhythmias such as atrial fibrillation (AF), today announced €36 million in new Series B funding,...
January 5, 2023

Gilde Healthcare company Adcendo Aps Announces License Agreement with Duality Biologics on Next-generation ADC Platform

Adcendo licenses Duality’s DITAC (Duality Immune Toxin Antibody Conjugates) linker/payload platform for its lead uPARAP-ADC program Agreement based on synergies between Adcendo and Duality in generating breakthrough ADCs in hard-to-treat cancers Adcendo ApS (“Adcendo”), a...
January 5, 2023